Haloperidol Crescent Pharma

Haloperidol Crescent Pharma is a prescription oral formulation containing the active ingredient haloperidol. It is marketed in the European Union and belongs to the butyrophenone class of antipsychotic agents. The product is supplied without a specific strength listed in the source data, and it is intended for use under medical supervision. It is prescribed for the management of several psychiatric conditions and is regulated as a prescription‑only medication.

Haloperidol Crescent Pharma is indicated for the treatment of several psychiatric disorders where dopamine blockade is therapeutic.

- Schizophrenia, including acute exacerbations and maintenance therapy. - Acute psychotic episodes associated with mood disorders or substance use. - Tourette syndrome, particularly for reducing motor and vocal tics. - Severe agitation or aggression in hospitalized patients when rapid control is needed. - Adjunctive therapy for other conditions as determined by a qualified clinician.

Side effects of haloperidol may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Drowsiness, fatigue, or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth, constipation, or blurred vision.

Serious: - Neuroleptic malignant syndrome, a potentially life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary movements. - Significant cardiac effects, including QT interval prolongation.

Before initiating Haloperidol Crescent Pharma, clinicians should assess patient history and monitor for specific risks associated with antipsychotic therapy.

- Evaluate cardiovascular status, especially for QT prolongation risk. - Review personal or family history of movement disorders. - Assess liver and renal function, adjusting therapy as needed. - Use caution in patients with a history of seizures or electrolyte imbalance. - Monitor for signs of neuroleptic malignant syndrome during treatment. - Consider pregnancy and lactation status; safety data are limited.

Haloperidol can interact with other medications, influencing its effectiveness or increasing adverse effects; interactions are grouped by clinical relevance.

Avoid: - Concurrent use with other dopamine antagonists or high‑potency antipsychotics. - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.

Use with caution: - CYP3A4 inducers like carbamazepine or rifampin, which may lower haloperidol levels. - Medications that prolong the QT interval, including certain antiarrhythmics and fluoroquinolones. - Central nervous system depressants, for example benzodiazepines or opioids.